26-Apr-2024
BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
Business Wire (Fri, 26-Apr 10:34 AM ET)
BeiGene (BGNE) Receives a Hold from Bernstein
TipRanks (Thu, 25-Apr 3:45 AM ET)
Business Wire (Wed, 24-Apr 4:01 PM ET)
EU regulators approve BeiGene's tislelizumab for lung cancer
Seeking Alpha News (Tue, 23-Apr 12:15 PM ET)
Business Wire (Tue, 23-Apr 6:00 AM ET)
Business Wire (Thu, 14-Mar 4:28 PM ET)
Pi Health Raises Over $30M in Series A to Revolutionize Cancer Care and Clinical Trials
Business Wire (Thu, 14-Mar 10:12 AM ET)
Business Wire (Wed, 13-Mar 8:00 AM ET)
Business Wire (Thu, 7-Mar 5:19 PM ET)
Business Wire (Wed, 6-Mar 6:00 AM ET)
BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.
Beigene Ltd. - American Depositary Shares trades on the NASDAQ stock market under the symbol BGNE.
As of April 26, 2024, BGNE stock price climbed to $153.58 with 204,501 million shares trading.
BGNE has a beta of 1.51, meaning it tends to be more sensitive to market movements. BGNE has a correlation of 0.16 to the broad based SPY ETF.
BGNE has a market cap of $16.05 billion. This is considered a Large Cap stock.
Last quarter Beigene Ltd. - American Depositary Shares reported $634 million in Revenue and -$3.53 earnings per share. This fell short of revenue expectation by $-151,000 and exceeded earnings estimates by $.20.
In the last 3 years, BGNE stock traded as high as $426.56 and as low as $118.18.
The top ETF exchange traded funds that BGNE belongs to (by Net Assets): IBB, FBT, BBH, QQQJ, AVEM.
BGNE has underperformed the market in the last year with a return of -37.6%, while the SPY ETF gained +27.4%. In the last 3 month period, BGNE fell short of the market, returning -5.1%, while SPY returned +4.6%. However, in the most recent 2 weeks BGNE has outperformed the stock market by returning +8.7%, while SPY returned -0.5%.
BGNE support price is $144.94 and resistance is $152.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BGNE stock will trade within this expected range on the day.